By analyzing these interactions, this discussion aims to shed light on the potential of GLP-1 agonists through their modulation of the gut microbiota, serving as key components in effective obesity treatment. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.